Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.

Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.

The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being.

The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being.

The invention relates to pharmaceutical compositions comprising at least one inhibitor of a histon-deacetylase (HDACi) and at least one agonist of Toll-like-receptor 7 and/or 8 (TLR7 and/or TLR8). The invention further relates to the aforementioned pharmaceutical compositions for use in a method of treating or preventing a disease. The invention further relates to the aforementioned pharmaceutical compositions for use in a method of treating or preventing cancer. The invention further relates to a method of treating or preventing cancer. The invention further relates to a kit of parts comprising at least one inhibitor of a histon-deacetylase (HDACi) and at least one agonist of Toll-like-receptor 7 and/or 8 (TLR7 and/or TLR8). The invention further relates to a cancer cell contacted with the pharmaceutical composition of the invention, wherein said cancer cell has an upregulated expression of one or more single-stranded RNA (ssRNA) genes, wherein the one or more ssRNA genes with upregulated expression are preferably endogenous retroviral (HERV) genes. The invention further relates to an in vitro method for contacting cancer cells with the pharmaceutical composition of the invention. The invention further relates to a population of cancer cells obtainable by the in vitro method of the invention.

The invention relates to pharmaceutical compositions comprising at least one inhibitor of a histon-deacetylase (HDACi) and at least one agonist of Toll-like-receptor 7 and/or 8 (TLR7 and/or TLR8). The invention further relates to the aforementioned pharmaceutical compositions for use in a method of treating or preventing a disease. The invention further relates to the aforementioned pharmaceutical compositions for use in a method of treating or preventing cancer. The invention further relates to a method of treating or preventing cancer. The invention further relates to a kit of parts comprising at least one inhibitor of a histon-deacetylase (HDACi) and at least one agonist of Toll-like-receptor 7 and/or 8 (TLR7 and/or TLR8). The invention further relates to a cancer cell contacted with the pharmaceutical composition of the invention, wherein said cancer cell has an upregulated expression of one or more single-stranded RNA (ssRNA) genes, wherein the one or more ssRNA genes with upregulated expression are preferably endogenous retroviral (HERV) genes. The invention further relates to an in vitro method for contacting cancer cells with the pharmaceutical composition of the invention. The invention further relates to a population of cancer cells obtainable by the in vitro method of the invention.

The invention relates to pharmaceutical compositions comprising at least one inhibitor of a histon-deacetylase (HDACi) and at least one agonist of Toll-like-receptor 7 and/or 8 (TLR7 and/or TLR8). The invention further relates to the aforementioned pharmaceutical compositions for use in a method of treating or preventing a disease. The invention further relates to the aforementioned pharmaceutical compositions for use in a method of treating or preventing cancer. The invention further relates to a method of treating or preventing cancer. The invention further relates to a kit of parts comprising at least one inhibitor of a histon-deacetylase (HDACi) and at least one agonist of Toll-like-receptor 7 and/or 8 (TLR7 and/or TLR8). The invention further relates to a cancer cell contacted with the pharmaceutical composition of the invention, wherein said cancer cell has an upregulated expression of one or more single-stranded RNA (ssRNA) genes, wherein the one or more ssRNA genes with upregulated expression are preferably endogenous retroviral (HERV) genes. The invention further relates to an in vitro method for contacting cancer cells with the pharmaceutical composition of the invention. The invention further relates to a population of cancer cells obtainable by the in vitro method of the invention.

The invention relates to a composition for induction of activity of a nuclear receptor PPARγ and inhibition of HDAC in a subject in need thereof, which comprises a synergistic combination of benzoate and phenylbutyrate and/or phenylacetate in association with a pharmaceutical carrier.

Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.

Described herein are methods useful for the treatment of cancers in a canine subject with a pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. Also described herein are methods for identification of subjects with cancers that will benefit from administration of the pharmaceutical compositions comprising HD AC inhibitors, Rapamycin, Dasatinib, Lapatinib, Trametinib, Vorinostat, Imatinib, Crizotinib, Sorafenib, and combinations thereof. In certain aspects, the methods described herein further comprise administering a therapeutically effective amount of at least one additional anti-cancer agent.